Baltic Export, Good for Business, Lithuania, Markets and Companies, Medicine, Technology
International Internet Magazine. Baltic States news & analytics
Wednesday, 21.05.2025, 05:45
Sicor Biotech/TEVA will build a new pharmaceutical plant in Vilnius
Print version |
|---|
Once on stream, the multifunctional plant will double the production capacity of Sicor Biotech/TEVA, with over 95% of its biopharmaceuticals produced for export, writes LETA/ELTA.
The investment in the new plant reinforces Lithuania's position as a high-tech centre in the Baltic and Nordic region, according to Professor Vladas Algirdas Bumelis, General Manager of Sicor Biotech/TEVA Baltics. He said that "Lithuania's focus on a high-tech service economy has proven to be effective. An improved investment environment and the great potential of the country's scientists and biotech professionals are attracting foreign investors in growing numbers".
Prof Bumelis believes that Sicor Biotech/TEVA is now poised to gain a foothold in large markets like the US, Japan and Canada, where the company's Lithuanian-made products will soon become available. Medicines produced by the company have already been approved for sale in the European Union, Switzerland, Russia, Israel and Brazil.
The new Sicor Biotech/TEVA plant will create 49 new jobs and will be built next to the company's first plant on the Moletai Highway in Vilnius.
«The Baltic Course» Is Sold and Stays in Business!
